Conference on Semantics in Healthcare and Life Sciences (C-SHALS) 

Discussion Questions
C-SHALS 2009 will address a number of important discussion questions including:
Moderated Forum 1: BioMedicine
  • Tim Clark, Core Member, Harvard Initiative in Innovative Computing
  • Parsa Mirhaji, MD, Director, The University of Texas Health Science Center
DISCUSSION ISSUES:(Moderator: Eric Neumann)
1. What are some of the information challenges in biomedical studies in different disease areas (e.g., Alzheimers and Cancer)?
  2. Are medical record systems currently adequate for organizing patient info in support of the data analysis for your studies?
  3. Do you see other researchers and doctors using the knowledge your capturing, and if so in what way?
Moderated Forum 2: Semantic Web in Pharma
  • Dr. Philip Ashworth, UCB Pharma
  • Ranga Chandra Gudivada, Eli Lilly and Company
  • Jaime Melendez, Merck and Co., Inc.
  • Therese Vachon, Novartis Pharma AG
DISCUSSION ISSUES: (Moderator: Ted Slater)
  1. What experiences did you have in integrating your projects with existing data systems?
  2. What are some of the SW features that you found useful in the different apps?
  3. Can you identify any common elements in your approaches that would be applicable cross all your cases?
Moderated Forum 3: Biomarkers & Compounds
  • Jonas S. Almeida, University of Texas
  • Thomas N. Plasterer, PhD, BG Medicine
  • Antony J. Williams, ChemZoo Inc.
DISCUSSION ISSUES: (Moderator: Susie Stephens)
1. Do you see your challenges as mostly data management or knowledge discovery?
  2. Is sharing insights and models with other scientists an important part of your work?
  3. How much of your goals involve numeric computation, and how much are related to symbolic processing and reasoning?
Moderated Forum 4: Ontologies
  • Marco F. Ramoni, PhD, Harvard Medical School
  • Larisa Soldatova, University of Wales
  • Nigam Shah, Stanford University
DISCUSSION ISSUES: (Moderator: Joanne Luciano)
1. Do we need overarching high level ontologies before creating more specific ontologies?
  2. What are some methodologies for bridging different existing ontologies
  3. Should Thesauri be represented as complete ontologies, or using specialized models such as SKOS?
Moderated Forum 5: Knowledge Bases
  • Ted Slater, Pfizer
  • Bruce Aronow, Ph.D., Cincinnati Children's Hospital Medical Center, University of Cincinnati
  • Will Loging, Boehringer Ingelheim Pharmaceuticals, Inc.
DISCUSSION ISSUES: (Moderator: Mike Bevil)
1. How do you define what a knowledge base is, and how do you envision it being used by researchers?
2. Do you differentiate between absolute factual knowledge, and proposed models? Does this require different ontological representations?
  3. How do you see electronic knowledge becoming more wide-spread n R&D? Will it be a business differentiator and will it improve productivity?